Lonza raises outlook as biologics demand grows

Lonza executive discusses the evolving CGT landscape

BioProcess International learned about how advanced therapy developers and manufacturers are adapting to changing circumstances.

Lonza raises outlook as biologics demand grows

Lonza has raised its full-year margin outlook after reporting first-half sales of CHF3.4 billion, supported by demand across biologics, drug products, bioconjugates, microbial manufacturing, and small molecules. Sales from continuing operations increased by 16% at constant exchange rates and 11.2% at actual rates. Core earnings before interest, tax, depreciation, and amortisation reached CHF1.2 billion, producing a margin of 34.8%. During the pe…